Jan Poolman

Poolman earned his master’s degree from the University of Amsterdam (UVA) in 1975, where he studied chemistry and specialized in the field of microbiology.

He started his career as assistant-professor at the University of Amsterdam, Medical Microbiology department (1975-1986) and the Dutch Reference Laboratory for Bacterial Meningitis, including a NIH Fogarty Fellowship in 1982 and a thesis on the meningococcal cell surface structure.{{Cite web |title=Album Academicum |url=https://albumacademicum.uva.nl/cgi/b/bib/bib-idx?c=ap;cc=ap;lang=en;q1=cell%20walls;rgn1=educationdiscipline;type=boolean;view=reslist;sort=achternaam;fmt=long;page=reslist;size=1;start=13 |access-date=2024-04-22 |website=albumacademicum.uva.nl}} Next he became head of Bacterial Vaccine Research & Development (R&D) at the Dutch National Public Health Institute (RIVM, 1986-1996) initiating DTaPIPVHib, meningococcal and pneumococcal vaccine R&D activities, also acting as project leader for the newly created Dutch-Nordic Consortium combining activities from the Dutch and Scandinavian Public Health Institutes with a focus on pneumococcal vaccine R&D.

He then moved on to SmithKline Beecham Biologicals (now GSK Vaccines) in Rixensart, Belgium (1997-2011) as head of bacterial vaccine R&D contributing to the licensure of several bacterial vaccines including whole cell and acellular pertussis and Hib combinations, meningococcal and pneumococcal vaccines. From GSK Dr Poolman moved back from Belgium to The Netherlands to join the vaccine endeavor by Johnson & Johnson (2011-2024), creating a Bacterial Vaccine R&D team with projects centered around adult bacterial vaccines aiming to prevent bacteremia and sepsis induced by E. coli and S. aureus. Extraintestinal Pathogenic E. coli ExPEC 9-valent O-polysaccharide conjugate is currently undergoing a Phase 3 efficacy study evaluation.{{Cite web |last=Janssen Research & Development, LLC (2024-03-26). |title=Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years (Report). clinicaltrials.gov.ClinicalTrials.gov |url=https://clinicaltrials.gov/study/NCT04899336?cond=expec&rank=2 |access-date=2024-07-03 |website=clinicaltrials.gov}}

During his career Poolman contributed to two World Health Organization (WHO)-reports{{Cite web |title=60th report: WHO TRS N°977: 2009 |url=https://www.who.int/publications/i/item/9789241209779 |access-date=2025-01-10 |website=www.who.int; ISBN: 9789241209779; WHO Reference Number: WHO TRS N°977 |language=en}}{{Cite web |last=WHO Team - Immunization, Vaccines and Biologicals (IVB) |date=10 October 2024 |title=Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use: technical report |url=https://www.who.int/publications/i/item/9789240098787 |website=ISBN: 978-92-4-009878-7}} as an industry expert on bacterial vaccines. In 2009, Poolman contributed to a WHO report on the topic of pneumococcal conjugate vaccines. In 2023, he contributed to a WHO report as an industry expert on bacterial vaccines through a public consultation by sharing his perspectives on the role of bacterial vaccines in reducing AMR.

Poolman is a member of the Board of Trustees of the Jenner Vaccine Foundation.{{Cite web |title=The Jenner Vaccine Foundation |url=https://www.jenner.ac.uk/about/jenner-vaccine-foundation |access-date=2025-01-21 |website=www.jenner.ac.uk |language=en}} In addition, Poolman is a member of the Scientific Advisory Board of Inventprise{{Cite web |date=2024-03-08 |title=About Us - Inventprise |url=https://inventprise.com/about-us/#team |access-date=2025-01-21 |language=en-US}} and he is a member of the Scientific Advisory Board of the World Vaccine Congress Europe.{{Cite web |date=2025-01-16 |title=World Vaccine Congress Europe 2025 {{!}} Amsterdam |url=https://www.terrapinn.com/conference/world-vaccine-congress-europe/index.stm |access-date=2025-01-21 |website=World Vaccine Congress Europe 2025 |language=en}}

After his retirement in September 2024 from Johnson & Johnson, Dr Poolman now functions as scientific advisor for several companies and organizations. Poolman is scientific advisor of the [https://nividevelopment.dk/ Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI)].{{Cite web |title=Home |url=https://nividevelopment.dk/ |access-date=2025-03-22 |website=NIVI Development |language=en-US}}

Poolman has been an author or co-author of around 290 scientific publications on bacterial vaccines in his career of over 45 years; his publications have been cited more than 13,500 times. Key topics of his publications, exampled by references to the abstracts of a set of selected publications, are: Group B Meningococcus,{{Cite journal |last=Cartwright |first=K. |last2=Morris |first2=R. |last3=Rümke |first3=H. |last4=Fox |first4=A. |last5=Borrow |first5=R. |last6=Begg |first6=N. |last7=Richmond |first7=P. |last8=Poolman |first8=J. |date=1999-06-04 |title=Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins |url=https://pubmed.ncbi.nlm.nih.gov/10418910/ |journal=Vaccine |volume=17 |issue=20-21 |pages=2612–2619 |doi=10.1016/s0264-410x(99)00044-4 |issn=0264-410X |pmid=10418910}} Haemophilus influenzae type b (Hib),{{Cite journal |last=Poolman |first=J. |last2=Kaufhold |first2=A. |last3=De Grave |first3=D. |last4=Goldblatt |first4=D. |date=2001-03-21 |title=Clinical relevance of lower Hib response in DTPa-based combination vaccines |url=https://pubmed.ncbi.nlm.nih.gov/11257348/ |journal=Vaccine |volume=19 |issue=17-19 |pages=2280–2285 |doi=10.1016/s0264-410x(00)00517-x |issn=0264-410X |pmid=11257348}} Pertussis,{{Cite journal |last=Capiau |first=Carine |last2=Poolman |first2=Jan |last3=Hoet |first3=Bernard |last4=Bogaerts |first4=Hugues |last5=Andre |first5=Francis |date=2003-06-02 |title=Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: difficulties encountered and lessons learned |url=https://pubmed.ncbi.nlm.nih.gov/12744858/ |journal=Vaccine |volume=21 |issue=19-20 |pages=2273–2287 |doi=10.1016/s0264-410x(03)00107-5 |issn=0264-410X |pmid=12744858}} Pneumococcus{{Cite journal |last=Prymula |first=Roman |last2=Peeters |first2=Pascal |last3=Chrobok |first3=Viktor |last4=Kriz |first4=Pavla |last5=Novakova |first5=Elena |last6=Kaliskova |first6=Eva |last7=Kohl |first7=Igor |last8=Lommel |first8=Patricia |last9=Poolman |first9=Jan |last10=Prieels |first10=Jean-Paul |last11=Schuerman |first11=Lode |date=2006 |title=Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study |url=https://linkinghub.elsevier.com/retrieve/pii/S0140673606683049 |journal=The Lancet |language=en |volume=367 |issue=9512 |pages=740–748 |doi=10.1016/S0140-6736(06)68304-9|url-access=subscription }}, Meningococcus ACWY,{{Cite journal |last=Knuf |first=M. |last2=Kieninger-Baum |first2=D. |last3=Habermehl |first3=P. |last4=Muttonen |first4=P. |last5=Maurer |first5=H. |last6=Vink |first6=P. |last7=Poolman |first7=J. |last8=Boutriau |first8=D. |date=2010-01-08 |title=A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children |url=https://pubmed.ncbi.nlm.nih.gov/19887137/ |journal=Vaccine |volume=28 |issue=3 |pages=744–753 |doi=10.1016/j.vaccine.2009.10.064 |issn=1873-2518 |pmid=19887137}} ExPEC,{{Cite journal |last=Huttner |first=Angela |last2=Hatz |first2=Christoph |last3=van den Dobbelsteen |first3=Germie |last4=Abbanat |first4=Darren |last5=Hornacek |first5=Alena |last6=Frölich |first6=Rahel |last7=Dreyer |first7=Anita M. |last8=Martin |first8=Patricia |last9=Davies |first9=Todd |last10=Fae |first10=Kellen |last11=van den Nieuwenhof |first11=Ingrid |last12=Thoelen |first12=Stefan |last13=de Vallière |first13=Serge |last14=Kuhn |first14=Anette |last15=Bernasconi |first15=Enos |date=2017 |title=Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial |url=https://pubmed.ncbi.nlm.nih.gov/28238601/ |journal=The Lancet Infectious Diseases |volume=17 |issue=5 |pages=528–537 |doi=10.1016/S1473-3099(17)30108-1 |issn=1474-4457 |pmid=28238601}} and S. aureus{{Cite journal |last=Fernandez |first=Jeffrey |last2=Sanders |first2=Holly |last3=Henn |first3=Jessica |last4=Wilson |first4=Jolaine M. |last5=Malone |first5=Danielle |last6=Buoninfante |first6=Alessandra |last7=Willms |first7=Matthew |last8=Chan |first8=Rita |last9=DuMont |first9=Ashley L. |last10=McLahan |first10=Craig |last11=Grubb |first11=Kaitlyn |last12=Romanello |first12=Anthony |last13=van den Dobbelsteen |first13=Germie |last14=Torres |first14=Victor J. |last15=Poolman |first15=Jan T. |date=2022-04-19 |title=Vaccination With Detoxified Leukocidin AB Reduces Bacterial Load in a Staphylococcus aureus Minipig Deep Surgical Wound Infection Model |url=https://pubmed.ncbi.nlm.nih.gov/33895843/ |journal=The Journal of Infectious Diseases |volume=225 |issue=8 |pages=1460–1470 |doi=10.1093/infdis/jiab219 |issn=1537-6613 |pmc=9016470 |pmid=33895843}} {{Cite journal |last=Poolman |first=Jan T. |last2=Torres |first2=Victor J. |last3=Missiakas |first3=Dominique |last4=Welten |first4=Suzanne P. M. |last5=Fernandez |first5=Jeffrey |last6=DuMont |first6=Ashley L. |last7=O’Keeffe |first7=Anna |last8=Konstantinov |first8=Sergey R. |last9=Morrow |first9=Brian |last10=Burghout |first10=Peter |last11=Grijpstra |first11=Jan |last12=van Beers |first12=Miranda M. C. |last13=Anish |first13=Chakkumkal |last14=Beurret |first14=Michel |last15=Geurtsen |first15=Jeroen |date=2025-04-20 |title=A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models |url=https://www.nature.com/articles/s41541-025-01119-8 |journal=npj Vaccines |language=en |volume=10 |issue=1 |pages=1–13 |doi=10.1038/s41541-025-01119-8 |issn=2059-0105|pmc=12009994 }}.

Poolman is born 16 June 1951 in Broek in Waterland, the Netherlands; he is married and jointly with his second wife they have a mixed family with five children and two grandchildren.

{{reflist}}

{{DEFAULTSORT:Poolman, Jan}}

Category:1951 births

Category:Living people

Category:Dutch microbiologists